Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Biliary Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR PH 2 Enfortumab in Urothelial Pts-Cohort L
View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-Waco
Phase: I/II
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Waco
Title:
Registry study with Breast Cancer Index
View
Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)
Indication:
Breast Cancer
Location:
Texas Oncology-Waco
Phase: IV
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Breast Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Waco
Phase: III
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Cervical Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC
View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ
View
Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)
Indication:
Gastric Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
View
Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Waco
Phase: I
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph3b ABL001 in CML-CP +/-T315i
View
Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)
Indication:
Leukemia
Location:
Texas Oncology-Waco
Phase: III/IV
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
PH3 Nira Pembro Stg 3/4 NSCLC
View
Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)(213400)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR PH3 JNJ-61186372 Peme EGFR NSCLC
View
Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Waco
Phase: I/II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph3 Navi Ruxo Myelofibrosis
View
Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Indication:
Myelofibrosis
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Biomarker DNA Defect Men Prostate
View
Description: Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Waco
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Waco
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Waco
Phase: I/II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Solid Tumors
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)
Indication:
Solid Tumors
Location:
Texas Oncology-Waco
Phase: II
Title:
STAR PH 2 Enfortumab in Urothelial Pts-Cohort L
View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Waco
Phase: I/II
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Waco
Phase: II
Title:
Ph2 Basket Tucat+Tras ST HER2 Alt
View
Description: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)
Indication:
Uterine Cancer
Location:
Texas Oncology-Waco
Phase: II